Sanofi SA / Kymera Therapeutics, Inc.

Immune-Inflammatory Diseases (IRAK4 Targeted Protein Degradation)

3M US cases/yr · $63.0B Global immunology therapeutics market 2020 · ~$2.15B Total deal BD value (up to, incl. milestones + equity)

Disease Overview

The Sanofi-Kymera IRAK4 partnership targets a portfolio of high-prevalence immune-inflammatory indications anchored by hidradenitis suppurativa (HS), atopic dermatitis (AD), and rheumatoid arthritis (RA). HS affects roughly 1% of U.S. adults (~3 million patients) with high unmet need despite the launch of Humira and Cosentyx; AD affects approximately 16.5 million U.S. adults and 9.6 million children, with the moderate-to-severe segment representing the commercial epicenter; RA affects approximately 1.3 million U.S. adults. IRAK4 (interleukin-1 receptor-associated kinase 4) sits at the convergence of the IL-1 receptor and Toll-like receptor signaling cascades, driving NF-kB activation and downstream cytokine production (IL-6, TNF). Targeted protein degradation via heterobifunctional small molecules (PROTACs) offers a differentiated mechanism versus kinase inhibition because IRAK4 has both kinase and scaffolding functions — only degradation eliminates the scaffolding activity. WAC pricing for branded biologics in the immunology space ranges $50K-90K annually for HS/AD/RA. The partnership covers KT-474 (now SAR444656) plus a second undisclosed program.

Competitive Landscape

The IRAK4 and broader immune-inflammatory landscape is dense and rapidly evolving. Anti-TNF biologics (Humira/adalimumab AbbVie, Enbrel/etanercept Amgen, Remicade/infliximab Janssen) remain franchise leaders despite biosimilar erosion. IL-17 inhibitors (Cosentyx/secukinumab Novartis, Taltz/ixekizumab Lilly, Bimzelx/bimekizumab UCB) and IL-23 inhibitors (Skyrizi/risankizumab AbbVie, Tremfya/guselkumab Janssen) drive growth in psoriasis and HS. JAK inhibitors (Rinvoq/upadacitinib AbbVie, Cibinqo/abrocitinib Pfizer, Olumiant/baricitinib Lilly) target oral immunology including AD and RA but face boxed warnings. IRAK4 kinase inhibitors include zimlovisertib (PF-06650833, Pfizer Phase 2 in HS/RA) and BAY 1834845 (Bayer). Other targeted protein degraders in immunology include Arvinas/Pfizer's ARV-471 (estrogen receptor) and Nurix's NX-2127 (BTK degrader). KT-474 differentiates as the first IRAK4 degrader in clinical development, with Phase 1 healthy volunteer data showing greater than 95% IRAK4 knockdown supporting Phase 2 in HS and AD launched late 2022.